Active, not recruitingInterventional · Phase 3NCT04849728 ↗A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3
RecruitingInterventional · Phase 2NCT05832229 ↗Liver Cirrhosis Network (LCN) Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (RESCU): A Double-Blind Randomized, Placebo-Controlled Phase 2 StudyRobert S. BrownPIInterventionDrug: RosuvastatinDatesDec 2023 – Aug 2029 (est.)SponsorNational Institute of Diabetes & Digestive & Kidney DiseasesCirrhosisCirrhosis, LiverCirrhosis Early+5 more
RecruitingInterventional · Phase 3NCT06318169 ↗A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and FibrosisSonal KumarPIInterventionBiological: Pegozafermin · Other: PlaceboDatesMar 2024 – Feb 2029 (est.)Sponsor89Bio INCMetabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
RecruitingInterventional · Phase 3NCT06419374 ↗A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ENLIGHTEN-Cirrhosis)Sonal KumarPIInterventionBiological: Pegozafermin · Drug: PlaceboDatesMay 2024 – Jun 2028 (est.)Sponsor89Bio INCMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
RecruitingInterventional · Not applicableNCT07046429 ↗Effect of Supplemental Nightly Melatonin On REM and Cognition in Hepatic Encephalopathy (SNORE-HE) TrialAdam BuckholzPIInterventionDietary supplement: Melatonin tablet 3 mg once daily · Dietary supplement: ThiamineDatesAug 2025 – Dec 2026 (est.)SponsorWeill Medical College of Cornell UniversityHepatic EncephalopathyCovert Hepatic EncephalopathyCirrhosis+1 more
RecruitingInterventional · Phase 2NCT07335601 ↗Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate MGL-3196 (Resmetirom) in Patients With MASH Who Have Undergone Liver Transplant for MASH Cirrhosis or Other EtiologiesDanielle BrandmanPIInterventionDrug: Resmetirom · Drug: PlaceboDatesDec 2025 – Aug 2028 (est.)SponsorMadrigal Pharmaceuticals, Inc.MASH - Metabolic Dysfunction-Associated Steatohepatitis
TerminatedInterventional · Phase 2/3NCT04365868 ↗A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH CirrhosisSonal KumarPIInterventionDrug: belapectin · Drug: PlaceboDatesJun 2020 – Mar 2025· Results postedSponsorGalectin TherapeuticsPrevention of Esophageal VaricesNASH - Nonalcoholic SteatohepatitisCirrhosis
CompletedInterventional · Phase 2NCT05309200 ↗A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Adaptive Dose-Ranging Study to Assess Safety and Efficacy of Intravenous OCE-205 in Adults Diagnosed With Cirrhosis With Ascites Who Have Developed Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI)Robert S. BrownPIInterventionDrug: OCE-205 · Drug: PlaceboDatesApr 2022 – Sep 2023SponsorOcelot Bio, Inc.CirrhosisAscitesHepatorenal Syndrome+1 more